Nalu Medical Inc Announces Positive Results Of Us Spinal Cord

Nalu Medical Inc Announces Positive Results Of Us Spinal Cord Nalu medical, inc (“nalu”) is a carlsbad, california based company that has successfully miniaturized neurostimulation implants for the management of chronic intractable pain across a variety of targets with both spinal cord stimulation (scs) and peripheral nerve stimulation (pns) indications. Nalu medical inc. has released results of the scs npower u.s. clinical study that evaluated use of the nalu scs system to treat patients suffering from chronic intractable trunk and or limb pain, including unilateral or bilateral pain.

Nalu Medical Inc On Linkedin Spinal Cord Stimulator The scs npower us clinical study was a prospective, post market observational study conducted at 15 comprehensive pain centers in the us. The strong npower study results in scs reflect nalu’s commitment to providing differentiated clinical and health economic evidence to support the adoption and use of our unique neurostimulation system for chronic intractable pain in both spinal cord stimulation and peripheral nerve stimulation.”. “adding the highly differentiated nalu medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations.”. These results confirm the positive clinical outcomes from the comfort trial, the first nalu pns rct, and provide the first level 1 confirmatory evidence for a permanently implanted pns device for treating chronic pain.

Nalu Medical Inc Announces Publication Of Two Spinal Cord “adding the highly differentiated nalu medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations.”. These results confirm the positive clinical outcomes from the comfort trial, the first nalu pns rct, and provide the first level 1 confirmatory evidence for a permanently implanted pns device for treating chronic pain. Longitude portfolio company nalu medical, inc. recently announced publication of the scs npower™ us clinical study in the pain physician journal that reports on clinical outcomes related to. These results confirm the positive clinical outcomes from the comfort trial, the first nalu pns rct, and provide the first level 1 confirmatory evidence for a permanently implanted pns device for treating chronic pain. The scs npower us clinical study was a prospective, post market observational study conducted at 15 comprehensive pain centres in the usa. the nalu neurostimulation system was evaluated in 35 subjects with chronic low back and leg pain from baseline to three months. “these robust results reinforce the efficacy and safety of the nalu neurostimulation system with consistent pain relief across multiple anatomical targets at all timepoints, from 3 to 24.